• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.喹诺酮类药物对分枝杆菌的构效关系:8位结构修饰的影响
Antimicrob Agents Chemother. 1996 Oct;40(10):2363-8. doi: 10.1128/AAC.40.10.2363.
2
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.喹诺酮类抗菌药物对分枝杆菌的构效关系:N-1位和C-7位结构变化的影响
J Med Chem. 1996 Feb 2;39(3):729-35. doi: 10.1021/jm9507082.
3
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.N-1-叔丁基取代喹诺酮类:体外抗鸟分枝杆菌活性及构效关系研究
Antimicrob Agents Chemother. 1996 Nov;40(11):2637-43. doi: 10.1128/AAC.40.11.2637.
4
Activity of quinolones against mycobacteria.喹诺酮类药物对分枝杆菌的活性。
Drugs. 1995;49 Suppl 2:67-75. doi: 10.2165/00003495-199500492-00011.
5
Activity of quinolones against mycobacteria.喹诺酮类药物对分枝杆菌的活性。
Drugs. 1999;58 Suppl 2:19-22. doi: 10.2165/00003495-199958002-00004.
6
In-vitro activity of quinolones and macrolides against mycobacteria.喹诺酮类和大环内酯类药物对分枝杆菌的体外活性。
J Antimicrob Chemother. 1994 Sep;34(3):343-51. doi: 10.1093/jac/34.3.343.
7
Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.体外具有广谱抗分枝杆菌活性的硝基喹诺酮类药物。
Bioorg Med Chem Lett. 1999 Jun 21;9(12):1651-6. doi: 10.1016/s0960-894x(99)00251-6.
8
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
J Med Chem. 1995 Jul 21;38(15):2974-7. doi: 10.1021/jm00015a021.
9
[Antimycobacterial activities of a new quinolone, sparfloxacin].[一种新型喹诺酮类药物司帕沙星的抗分枝杆菌活性]
Kekkaku. 1991 Oct;66(10):643-9.
10
Preliminary study of the in vitro activity of irloxacin against mycobacteria.依诺沙星对分枝杆菌体外活性的初步研究。
Chemotherapy. 1995 May-Jun;41(3):204-7. doi: 10.1159/000239345.

引用本文的文献

1
Advances in antibacterial agents for .用于……的抗菌剂的进展
RSC Med Chem. 2024 Oct 18;16(1):37-49. doi: 10.1039/d4md00508b.
2
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.gyrB基因突变在泰国临床分离株的广泛耐药和超级耐药结核病中的作用
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5189-97. doi: 10.1128/AAC.00539-16. Print 2016 Sep.
3
Current prospects for the fluoroquinolones as first-line tuberculosis therapy.氟喹诺酮类药物作为一线抗结核治疗的现状。
Antimicrob Agents Chemother. 2011 Dec;55(12):5421-9. doi: 10.1128/AAC.00695-11. Epub 2011 Aug 29.
4
Anti-tubercular drug designing by structure based screening of combinatorial libraries.基于组合文库的结构筛选进行抗结核药物设计。
J Mol Model. 2011 Jul;17(7):1607-20. doi: 10.1007/s00894-010-0861-y. Epub 2010 Oct 16.
5
Role of porins for uptake of antibiotics by Mycobacterium smegmatis.孔蛋白在耻垢分枝杆菌摄取抗生素中的作用。
Antimicrob Agents Chemother. 2008 Sep;52(9):3127-34. doi: 10.1128/AAC.00239-08. Epub 2008 Jun 16.
6
Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegmatis using theoretical molecular descriptors.使用理论分子描述符对喹诺酮类抗菌剂针对偶然分枝杆菌和耻垢分枝杆菌的定量构效关系(QSAR)研究。
J Mol Model. 2007 Jan;13(1):111-20. doi: 10.1007/s00894-006-0133-z. Epub 2006 Aug 24.
7
On an aspect of calculated molecular descriptors in QSAR studies of quinolone antibacterials.喹诺酮类抗菌药物定量构效关系研究中计算分子描述符的一个方面。
Mol Divers. 2006 Aug;10(3):415-27. doi: 10.1007/s11030-006-9018-4. Epub 2006 Aug 2.
8
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.结核分枝杆菌DNA回旋酶:与喹诺酮类药物的相互作用及其与抗分枝杆菌药物活性的相关性。
Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8. doi: 10.1128/AAC.48.4.1281-1288.2004.
9
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.多重PCR扩增子构象分析用于快速检测耐氟喹诺酮结核分枝杆菌临床分离株中的gyrA突变
Antimicrob Agents Chemother. 2004 Feb;48(2):596-601. doi: 10.1128/AAC.48.2.596-601.2004.
10
Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.8-甲氧基对加替沙星抗肺炎链球菌II型拓扑异构酶活性的贡献。
Antimicrob Agents Chemother. 2003 Jan;47(1):77-81. doi: 10.1128/AAC.47.1.77-81.2003.

本文引用的文献

1
Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity.氟喹诺酮类药物在分枝杆菌中的作用:与在大肠杆菌中的作用相似性及通过细胞裂解液粘度进行检测
Antimicrob Agents Chemother. 1996 Jul;40(7):1594-9. doi: 10.1128/AAC.40.7.1594.
2
High-throughput screen for detecting antimycobacterial agents.用于检测抗分枝杆菌药物的高通量筛选
Antimicrob Agents Chemother. 1995 Oct;39(10):2235-8. doi: 10.1128/AAC.39.10.2235.
3
Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.新型6-氟-8-甲氧基喹诺酮类药物AM-1155在人体中的单剂量和多剂量药代动力学
Antimicrob Agents Chemother. 1995 Dec;39(12):2635-40. doi: 10.1128/AAC.39.12.2635.
4
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.喹诺酮类抗菌药物对分枝杆菌的构效关系:N-1位和C-7位结构变化的影响
J Med Chem. 1996 Feb 2;39(3):729-35. doi: 10.1021/jm9507082.
5
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.新合成喹诺酮类药物AM - 1155、司帕沙星和氧氟沙星的抗分枝杆菌活性比较
Antimicrob Agents Chemother. 1993 Jun;37(6):1259-63. doi: 10.1128/AAC.37.6.1259.
6
Anti-Mycobacterium avium activity of quinolones: in vitro activities.喹诺酮类药物对鸟分枝杆菌的活性:体外活性
Antimicrob Agents Chemother. 1993 Sep;37(9):1799-806. doi: 10.1128/AAC.37.9.1799.
7
Nationwide survey of drug-resistant tuberculosis in the United States.美国全国耐药结核病调查。
JAMA. 1994 Mar 2;271(9):665-71.
8
Structure-activity and structure-side-effect relationships for the quinolone antibacterials.喹诺酮类抗菌药物的构效关系和构效副作用关系。
J Antimicrob Chemother. 1994 Apr;33(4):685-706. doi: 10.1093/jac/33.4.685.
9
Multiple-drug-resistant tuberculosis.耐多药结核病
Clin Infect Dis. 1994 Jul;19(1):1-8; quiz 9-10. doi: 10.1093/clinids/19.1.1.
10
Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital.纽约市一家医院的结核病易感性模式、耐多药预测因素及其对初始治疗方案的影响。
Arch Intern Med. 1994 Oct 10;154(19):2161-7.

喹诺酮类药物对分枝杆菌的构效关系:8位结构修饰的影响

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

作者信息

Renau T E, Gage J W, Dever J A, Roland G E, Joannides E T, Shapiro M A, Sanchez J P, Gracheck S J, Domagala J M, Jacobs M R, Reynolds R C

机构信息

Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.

出版信息

Antimicrob Agents Chemother. 1996 Oct;40(10):2363-8. doi: 10.1128/AAC.40.10.2363.

DOI:10.1128/AAC.40.10.2363
PMID:8891145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163535/
Abstract

A series of quinolones with substitutions at the 8 position has been prepared as part of a study to examine the relationship between structural modifications at this position and activity against mycobacteria. The compounds were prepared by procedures described in the literature and were evaluated for their activities against Mycobacterium fortuitum and Mycobacterium smegmatis. The activities of the compounds against these two organisms were used as a measure of Mycobacterium tuberculosis activity. The results demonstrate that the contribution of the 8 position to antimycobacterial activity was dependent on the substituent at N-1 and was in the order (i) COMe approximately CBr > CCI > CH approximately CF approximately COEt > N > CCF3 when N-1 was cyclopropyl; (ii) N approximately CH > CF > COMe when N-1 was 2,4-difluorophenyl; (iii) N > or = CH when N-1 was tert-butyl; and (iv) N > CH when N-1 was ethyl. In general, derivatives with piperazine substitutions at C-7 were slightly less active against mycobacteria than the analogs with pyrrolidine substitutions, regardless of the pattern of substitution at the 8 position. Several of the best compounds were evaluated for their potential side effects as well as their activities against Mycobacterium aurum, Mycobacterium avium-M. intracellulare, and M. tuberculosis. These agents exhibited biological profiles similar to or better than those of the positive controls ciprofloxacin and sparfloxacin.

摘要

作为研究8位取代喹诺酮类化合物在该位置的结构修饰与抗分枝杆菌活性之间关系的一部分,已制备了一系列8位有取代基的喹诺酮类化合物。这些化合物采用文献中描述的方法制备,并对其抗偶然分枝杆菌和耻垢分枝杆菌的活性进行了评估。这些化合物对这两种微生物的活性被用作衡量结核分枝杆菌活性的指标。结果表明,8位对抗分枝杆菌活性的贡献取决于N-1位的取代基,顺序如下:(i)当N-1为环丙基时,COMe≈CBr>CCI>CH≈CF≈COEt>N>CCF3;(ii)当N-1为2,4-二氟苯基时,N≈CH>CF>COMe;(iii)当N-1为叔丁基时,N≥CH;(iv)当N-1为乙基时,N>CH。一般来说,无论8位的取代模式如何,C-7位有哌嗪取代的衍生物对分枝杆菌的活性略低于有吡咯烷取代的类似物。对几种最佳化合物的潜在副作用以及它们对金分枝杆菌、鸟分枝杆菌-胞内分枝杆菌和结核分枝杆菌的活性进行了评估。这些药物的生物学特性与阳性对照环丙沙星和司帕沙星相似或更好。